Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Protara Therapeutics, Inc. (Nasdaq: TARA) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. The company's prerecorded presentation will be available on September 13, 2021, at 7:00am ET, accessible via the Events and Presentations section on their website. Protara focuses on developing therapies for cancer and rare diseases, including TARA-002 for bladder cancer and lymphatic malformations, as well as IV Choline Chloride for intestinal failure-associated liver disease.

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021.

The prerecorded presentation will become available on Monday, September 13, 2021 at 7:00am ET and can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived on the Company’s website for 90 days following the presentation.

About Protara Therapeutics, Inc.

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

FAQ

When will Protara Therapeutics present at the H.C. Wainwright conference?

Protara Therapeutics will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

What is the date and time for Protara's presentation availability?

Protara's prerecorded presentation will be available on September 13, 2021, at 7:00am ET.

How can I access Protara's presentation from the H.C. Wainwright conference?

You can access Protara's presentation by visiting the Events and Presentations section of their website.

What are the main therapies Protara Therapeutics is developing?

Protara's main therapies include TARA-002 for non-muscle invasive bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease.

How long will Protara's presentation be available online?

Protara's presentation will be archived on their website for 90 days following the live presentation.